Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | GLI1 | P08151 | 1/20 | 0.30 |
| ▸ | GLI2 | P10070 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769079 | 0.78 | NPC1 (0.46) | ESRRGADORA2AADORA2B | |
| SCHEMBL21769012 | 0.67 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL21768996 | 0.67 | ALDH1A1 (0.43) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21768908 | 0.66 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL6957896 | 0.64 | ESR1 (0.46) | ESR1ESR2ESRRGALDH1A1ALDH2 | |
| SCHEMBL21780006 | 0.64 | MAPT (0.39) | ESR1ALDH1A1 | |
| SCHEMBL21769073 | 0.62 | KDM4E (0.32) | — | |
| SCHEMBL21769082 | 0.61 | CHRM4 (0.37) | ALDH1A1ADORA2AADORA2B | |
| SCHEMBL21769044 | 0.60 | POLB (0.43) | ALDH1A1ADORA2AADORA2B | |
| SCHEMBL21768831 | 0.60 | POLB (0.40) | ALDH1A1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200079793-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3616753-A1 | COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079793-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | ADORA2A, ADORA2B, ADORA3 | HCRTR1 308/4885HCRTR2 171/4885ESR1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.